Supplemental Table 2 from MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 2. Clinical and pathologic data for 33 subjects with papillary thyroid cancer.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362433341